An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients

Trial Profile

An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Aug 2013 Planned end date changed from 1 Feb 2008 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Actual start date changed from Feb 2006 to May 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top